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Peroxisome proliferator-activated receptor a
(PPARa) regulates the utilization of fat as an en-
ergy source during starvation and is the molec-
ular target for the fibrate dyslipidemia drugs.
Here, we identify the endocrine hormone fibro-
blast growth factor 21 (FGF21) as a mediator
of the pleiotropic actions of PPARa. FGF21 is
induced directly by PPARa in liver in response
to fasting and PPARa agonists. FGF21 in turn
stimulates lipolysis in white adipose tissue and
ketogenesis in liver. FGF21 also reduces phys-
ical activity and promotes torpor, a short-term
hibernation-like state of regulated hypothermia
that conserves energy. These findings demon-
strate an unexpected role for the PPARa-
FGF21 endocrine signaling pathway in regulat-
ing diverse metabolic and behavioral aspects
of the adaptive response to starvation.
INTRODUCTION
Mammals have evolved complex metabolic and behav-
ioral responses to survive extended periods of nutrient
deprivation. A key aspect of the overall adaptive response
is the shift from carbohydrates to ketone bodies as a pri-
mary fuel source. During fasting and starvation, fatty acids
are mobilized from white adipose tissue (WAT) to liver,
where they are oxidized to acetyl-CoA. The acetyl-CoA
is then used to synthesize ketone bodies, including b-
hydroxybutyrate and acetoacetate, which are reconverted
to acetyl-CoA in other tissues and oxidized in the tricar-
boxylic acid cycle to produce energy (Fukao et al., 2004).CDuring prolonged fasts, ketone bodies provide nearly half
of the body’s total energy and up to 70% of the energy
required by the brain (Cahill, 2006). In addition to altering
their fuel sources, many small mammals conserve energy
when food is scarce by undergoing periodic bouts of
torpor, a hibernation-like state of regulated hypothermia
generally lasting several hours (Geiser, 2004).
Peroxisome proliferator-activated receptor a (PPARa), a
nuclear receptor activated by fatty acids, is required for
the normal adaptive response to starvation. PPARa binds
to DNA response elements as a heterodimer with the
retinoid X receptor (RXR) to regulate the transcription of
numerous genes involved in fatty acid transport and oxi-
dation (Kersten et al., 2000; Lefebvre et al., 2006). Among
the genes regulated directly by PPARa in liver are those
encoding acyl-CoA oxidase (ACOX1) (Tugwood et al.,
1992), which is involved in peroxisomal b-oxidation of fatty
acids; carnitine palmitoyl transferase 1a (CPT1a) (Erol
et al., 2004; Hsu et al., 2001), which transports fatty acids
across the outer mitochondrial membrane; and hydroxy-
methylglutaryl-CoA synthase 2 (HMGCS2) (Erol et al.,
2004; Hsu et al., 2001; Rodriguez et al., 1994), which cat-
alyzes a key step in ketone-body synthesis. Mice lacking
PPARa accumulate copious amounts of hepatic triglycer-
ide and become hypoketonemic and hypoglycemic during
fasting and starvation (Hashimoto et al., 2000; Kersten
et al., 1999; Leone et al., 1999).
Fibroblast growth factor 21 (FGF21) is a member of a
subfamily of FGFs, also including FGF15 and FGF23, that
function as endocrine hormones (Itoh and Ornitz, 2004;
Kharitonenkov et al., 2005). FGF15 and FGF23 have im-
portant roles in regulating bile acid and phosphate metab-
olism, respectively (Houten, 2006; Yu and White, 2005).
Recent findings show that FGF21, which is expressed in
liver and pancreas, also regulates metabolism. Adminis-
tration of FGF21 to leptin-deficient rodents decreasesell Metabolism 5, 415–425, June 2007 ª2007 Elsevier Inc. 415
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FGF21 Regulates FastingFigure 1. FGF21 mRNA Levels Are Induced during Fasting by PPARa
(A) Wild-type (WT) and PPARa/ mice were administered either GW7647 (GW; 5 mg/kg by oral gavage) or vehicle (Veh) and killed 14 hr later. FGF21
mRNA levels were measured by RT-qPCR. (n = 5 mice per group.) In this and all other figures, error bars represent the mean ± SEM.
(B) Primary cultures of human hepatocytes were treated for 12 hr with GW7647 (GW; 1 mM) or vehicle (Veh). FGF21 mRNA levels were measured by
RT-qPCR.
(C) WT and PPARa/ mice were killed in the fed state, after a 12 hr fast, or 12 hr after refeeding. FGF21 mRNA levels were measured by RT-qPCR.
(n = 4 mice/group.) The fold induction relative to fed WT mice is shown above each bar.
(D) Cell-based reporter assays were performed in CV-1 cells cotransfected with the FGF211497/+5-luciferase reporter in the presence of PPARa
expression plasmid or control plasmid (CMX). Cells were treated with either vehicle (white bars) or 100 nM GW7647 (black bars).
(E) Cell-based reporter assays were performed in CV-1 cells cotransfected with the indicated FGF21-luciferase reporter plasmids in the presence of
control plasmid (CMX; white bars) or PPARa expression plasmid (black bars). Cells were treated with 100 nM GW7647.
(F) Chromatin immunoprecipitation assays were performed using liver tissue and either PPARa antibodies (black bars) or control IgG (white bars) and
primers to the FGF21 proximal promoter (1119 to 1044) or a control region (6533 to 6470).serum glucose and triglyceride concentrations and en-
hances insulin sensitivity and glucose clearance (Kharito-
nenkov et al., 2005). Mice in which FGF21 is overex-
pressed in liver are resistant to diet-induced weight gain
(Kharitonenkov et al., 2005). In diabetic monkeys, FGF21
administration decreases fasting serum glucose, triglycer-
ide, and insulin concentrations and causes small but sig-
nificant weight loss (Kharitonenkov et al., 2007). It also
reduces serum LDL cholesterol levels and raises HDL
cholesterol concentrations (Kharitonenkov et al., 2007).
While these studies demonstrate that pharmacological
administration of FGF21 has broad metabolic effects, little
is known about its physiological function. In this report, we
demonstrate that FGF21 is markedly induced by PPARa in
liver during fasting to regulate key aspects of the adaptive
starvation response.
RESULTS
FGF21 Is Induced during Fasting by PPARa
It was previously shown that the nuclear bile acid receptor
FXR regulates FGF15 in ileum (Inagaki et al., 2005; Li et al.,
2005). As part of a systematic analysis to determine416 Cell Metabolism 5, 415–425, June 2007 ª2007 Elsevier Incwhether other nuclear receptors regulate FGFs, we found
that PPARa regulates FGF21 in liver. Real-time quantita-
tive PCR (RT-qPCR) analysis showed that FGF21 mRNA
levels were induced 25-fold in liver in response to
GW7647, a PPARa-selective agonist (Brown et al., 2001)
(Figure 1A). In PPARa/ mice, basal FGF21 mRNA levels
were decreased 5-fold, and there was no induction by
GW7647 (Figure 1A). FGF21 was also induced by
GW7647 in primary cultures of human hepatocytes (Fig-
ure 1B). Thus, PPARa regulates FGF21 in both mouse liver
and human hepatocytes. FGF21 mRNA was not increased
by GW7647 in pancreas, where it is also expressed (data
not shown).
Since PPARa plays a prominent role in the starvation
response, we next examined whether FGF21 is regulated
by fasting. FGF21 mRNA levels were increased 28-fold
after a 12 hr fast (Figure 1C). Refeeding for 12 hr reduced
FGF21 mRNA to prefasting levels. While induction of
FGF21 by fasting was greatly diminished in PPARa/
mice, fasting still caused a 5-fold increase in FGF21
mRNA (Figure 1C). These data demonstrate that FGF21
is induced during fasting by PPARa but that other path-
ways also contribute..
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To assess whether FGF21 is regulated directly by PPARa,
an FGF21 promoter fragment extending from1497 to +5
was used to generate the FGF211497/+5-luciferase re-
porter. In transfection assays performed in CV-1 cells, re-
porter activity was induced 5-fold by PPARa in the pres-
ence of GW7647 (Figure 1D). Analysis of a series of 50
deletion mutants showed that truncation of the FGF21
promoter to 977 resulted in loss of most of the PPARa
response, and deletion to 66 eliminated it entirely (Fig-
ure 1E). In electrophoretic mobility shift assays, PPARa
bound as an RXRa heterodimer to two sequence elements
located between1093 and1057 and between98 and
53 (see Figure S1 in the Supplemental Data available
with this article online). To determine whether PPARa
binds to the FGF21 promoter in liver, chromatin immuno-
precipitation experiments were performed using mouse
liver tissue. PPARa binding to the FGF21 promoter was
detected using primers extending from 1119 to 1044,
but not with primers that amplify a control region from
6533 to 6470 (Figure 1F). Thus, PPARa directly regu-
lates FGF21 expression.
FGF21 Induces Ketogenesis
To study the physiological effects of FGF21, transgenic
mice were generated in which the mouse FGF21 coding
region was inserted into an apolipoprotein E (ApoE) pro-
moter construct that drives transgene expression chroni-
cally in the liver (Simonet et al., 1993). As measured by
RT-qPCR, FGF21 mRNA was present in liver at 50-fold
higher concentrations in FGF21 transgenic mice than in
fasted wild-type mice (data not shown). The FGF21 trans-
genic mice had significant reductions in serum choles-
terol, glucose, and insulin (Table S1). These data are
similar to those reported recently by another group that
independently generated FGF21 transgenic mice using
the ApoE promoter (Kharitonenkov et al., 2005).
Since PPARa/ mice have a prominent fasting pheno-
type that includes impaired ketogenesis and hepatic stea-
tosis (Hashimoto et al., 2000; Kersten et al., 1999; Leone
et al., 1999), we measured serum b-hydroxybutyrate
and hepatic triglyceride concentrations in wild-type and
FGF21 transgenic mice under fed and fasted conditions.
Notably, in the fed state, serum concentrations of b-
hydroxybutyrate were increased 5-fold in FGF21 trans-
genic mice compared to wild-type mice (Figure 2A). The
increase in ketone-body levels was accompanied by sig-
nificant decreases in serum and hepatic triglyceride con-
centrations (Figures 2B and 2C). Under fasted conditions,
when endogenous FGF21 is already markedly elevated,
only serum triglyceride concentrations were significantly
altered between wild-type and FGF21 transgenic mice
(Figures 2A–2C).
The increase in serum b-hydroxybutyrate concentra-
tions in fed FGF21 transgenic mice suggested that FGF21
induces ketogenesis. To examine this possibility directly,
total ketone-body production was measured in isolated
perfused livers from fed wild-type and FGF21 transgenic
mice. Ketogenesis was increased 30% in livers fromCFGF21 transgenic mice (Figure 2D). By comparison, fast-
ing alone induces ketone production by 60% in isolated
rodent livers perfused with 0.5 mM oleate (Scholz et al.,
1984). These data suggest that FGF21 contributes sub-
stantially to fasting-induced ketogenesis.
We next examined whether shorter-term administration
of recombinant FGF21 recapitulates the effects seen in
FGF21 transgenic mice. Wild-type mice and PPARa/
mice, which have low FGF21 mRNA levels in liver (Fig-
ure 1A), were injected with recombinant FGF21 or control
saline for 3 days, at which point serum b-hydroxybutyrate
and triglyceride concentrations were measured in the
fed state. After a subsequent 24 hr fast, serum b-hydrox-
ybutyrate and triglyceride levels and hepatic triglyceride
concentrations were measured. In the fed state, FGF21 in-
creased serum b-hydroxybutyrate concentrations 2- to
3-fold in both wild-type and PPARa/ mice and caused
a corresponding decrease in serum triglyceride concen-
trations (Figures 3A and 3B). As expected, fasting in-
creased serum b-hydroxybutyrate concentrations in wild-
type mice but had no effect in PPARa/ mice (Figure 3A).
Whereas FGF21 had no effect on the already high serum
b-hydroxybutyrate levels in fasted wild-type mice, it in-
creased b-hydroxybutyrate concentrations 3-fold in
fasted PPARa/ mice, restoring them to 30% of wild-
type levels (Figure 3A). FGF21 administration also caused
a significant reduction of triglyceride accumulation in livers
of fasted PPARa/ mice (Figure 3C). FGF21 had no effect
on the hypoglycemia that occurs in fasted PPARa/ mice
Figure 2. FGF21 Transgenic Mice Exhibit Increased Ketogen-
esis
(A–C) Serum b-hydroxybutyrate (A) and triglyceride (B) concentrations
and hepatic triglyceride concentrations (C) were measured in wild-type
(WT) and FGF21 transgenic (Tg) mice either in the fed state or after
a 24 hr fast. (n = 4 per group.)
(D) Total ketone-body production was measured using perfused livers
from WT and Tg mice. (n = 4–5 mice per group.). *p < 0.05; **p < 0.01;
***p < 0.001.ell Metabolism 5, 415–425, June 2007 ª2007 Elsevier Inc. 417
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verses the hypoketonemia and hepatic steatosis that oc-
cur during fasting in PPARa/ mice.
FGF21 Induces Lipolysis
Both CPT1a and HMGCS2 mediate crucial steps in keto-
genesis (Drynan et al., 1996; Hegardt, 1999), and their
genes are regulated directly by PPARa (Erol et al., 2004;
Hsu et al., 2001; Rodriguez et al., 1994). Neither CPT1a
nor HMGCS2 mRNA levels were significantly changed in
FGF21 transgenic mice compared to wild-type mice (Fig-
ure 4A). However, protein concentrations of both CPT1a
and HMGCS2 were significantly increased in livers of
FGF21 transgenic mice (Figure 4A and Figure S2), sug-
gesting that FGF21 stimulates ketogenesis in part by
increasing CPT1a and HMGCS2 protein levels through a
posttranscriptional mechanism.
Figure 3. Recombinant FGF21 Injection Induces Ketogenesis
Serum b-hydroxybutyrate (A) and triglyceride (B) concentrations and
hepatic triglyceride concentrations (C) were measured in wild-type
(WT) and PPARa/ mice administered either FGF21 (FGF; 0.75 mg/
kg/day, subcutaneous) or vehicle (Veh) for 3 days. Serum was taken
from mice in the fed state or after a 24 hr fast as indicated. (n = 4
mice per group.) *p < 0.05; **p < 0.01. In (C), oil red O-stained liver sec-
tions from fasted PPARa/ mice administered either FGF21 or vehicle
are shown. Scale bars = 40 mm.418 Cell Metabolism 5, 415–425, June 2007 ª2007 Elsevier IncTo understand further how FGF21 induces ketogenesis,
microarray experiments were performed using mRNA pre-
pared from livers of wild-type and FGF21 transgenic mice.
No increase in ACOX1 or other prototypical PPARa target
genes was seen (data not shown). Interestingly, however,
dramatic increases were observed in the mRNAs encod-
ing a number of pancreatic lipases including pancreatic
lipase (PNLIP), pancreatic lipase-related protein 2
(PNLIPRP2), carboxyl ester lipase (CEL), and pancreatic
colipase (CLPS). The induction of these lipases was unex-
pected since they are normally expressed at only very low
Figure 4. FGF21 Induces Ketogenic Enzymes and Lipases in
Liver
(A) CPT1a and HMGCS2 mRNA and protein concentrations in livers
from fed wild-type (WT) and FGF21 transgenic (Tg) mice were mea-
sured by RT-qPCR and western blot analysis, respectively. Western
data for individual mice are shown in Figure S2. (n = 4 mice per group.)
*p < 0.05; **p < 0.01.
(B–E) Pancreatic lipase (PNLIP), pancreatic lipase-related protein 2
(PNLIPRP2), carboxyl ester lipase (CEL), and pancreatic colipase
(CLPS) mRNA levels were measured by RT-qPCR in livers from WT
and Tg mice (B), PPARa/ mice infected with either control (Con) or
FGF21-expressing (FGF) adenoviruses for 5 days (C), WT mice either
fed ad libitum or after a 12 hr fast (D), and WT mice administered vehi-
cle (Veh) or the PPARa agonist Wy14,643 (Wy; 0.1% in chow) for 5
days (E). (n = 4–5 mice per group.) Average Ct values are indicated
on the bars..
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expression of these genes was induced in FGF21 trans-
genic mice (Figure 4B), in PPARa/ mice infected with
an FGF21-expressing adenovirus (Figure 4C), in wild-
type mice fasted for 12 hr (Figure 4D), and in wild-type
mice administered the PPARa agonist Wy14,643 for 5
days (Figure 4E). While the Wy14,643 treatment regimen
resulted in the expected robust induction of FGF21 and
ACOX1 (Figure S3), mice fed chow containing Wy14,643
ate 20% less than mice fed the control diet and weighed
7% less at the end of the study (data not shown), which
complicates interpretation of these results. Nevertheless,
these data show that pancreatic lipases are induced by
fasting via the PPARa-FGF21 signaling pathway.
The observation that adipocytes from FGF21 transgenic
mice are substantially smaller than those from wild-type
mice (Kharitonenkov et al., 2005) (Figure 5A) led us to ex-
amine whether FGF21 also regulates lipase expression in
WAT. Although PNLIP, PNLIPRP2, CEL, and CLP mRNAs
were modestly upregulated in WAT from FGF21 trans-
genic mice, no increase was seen in WAT from PPARa/
mice infected with an FGF21-expressing adenovirus (data
not shown). However, levels of mRNAs encoding hor-
mone-sensitive lipase (HSL) and adipose triglyceride li-
pase (ATGL), the two predominant lipases in WAT, were
uniformly increased in FGF21 transgenic mice (Figure 5B),
in PPARa/ mice infected with an FGF21-expressing ad-
enovirus (Figure 5C), and in wild-type mice administered
Wy14,643 (Figure 5D). Wy14,643 treatment could poten-
tially induce lipase expression in WAT either indirectly by
inducing FGF21 in liver or directly by acting on the small
amount of PPARa present in WAT. A corresponding in-
crease in HSL and ATGL protein concentrations occurred
in WAT from FGF21 transgenic mice (Figure 5B and Fig-
ure S4). Consistent with increased lipase expression and
smaller adipocyte size, serum free fatty acid concentra-
tions were significantly increased in FGF21 transgenic
mice and in wild-type mice administered recombinant
FGF21 (Figure 5E). Surprisingly, urine concentrations of
adrenaline and noradrenaline, which have well-estab-
lished roles in inducing lipolysis (Collins et al., 2004),
were reduced in FGF21 transgenic mice (Figure S5), indi-
cating that FGF21 does not stimulate lipolysis by causing
a systemic increase in catecholamine levels.
To examine directly whether FGF21 induces lipolysis in
adipocytes, glycerol release was measured in 3T3-L1 ad-
ipocytes treated with either FGF21 or the b-adrenergic re-
ceptor agonist isoproterenol. As expected, isoproterenol
caused a time-dependent release of glycerol into the me-
dia (Figure 5F). Importantly, FGF21 also caused glycerol
release, albeit at reduced efficacy compared to isoproter-
enol (Figure 5F). The 0.5 nM concentration of FGF21 used
in these assays was saturating for lipolysis as determined
by dose-response analysis (data not shown). Thus, FGF21
stimulates lipolysis in adipocytes. Cotreatment with
0.5 nM FGF21 and 5 nM isoproterenol did not result in
any additional stimulation of lipolysis above that seen
with isoproterenol alone (Figure S6), suggesting that the
two hormones may act through a common pathway. NoCincrease in HSL or ATGL mRNA levels was seen in
response to FGF21 treatment in these in vitro studies
(data not shown), indicating that the changes that are
seen in the in vivo experiments may be part of an adaptive
response to longer-term FGF21 exposure.
FGF21 Enhances Torpor
The pancreatic lipases PNLIPRP2 and CLPS are induced
in liver and other tissues during the hibernation-like state
Figure 5. FGF21 Induces Lipolysis in White Adipose Tissue
(A) Hematoxylin and eosin-stained sections of epididymal white adi-
pose tissue (WAT) from wild-type (WT) and FGF21 transgenic (Tg) mice.
Scale bars = 40 mm.
(B) Hormone-sensitive lipase (HSL) and adipose triglyceride lipase
(ATGL) mRNA and protein concentrations in epididymal WAT from
fed WT and Tg mice were measured by RT-qPCR and western blot
analysis, respectively. Western data for individual mice are shown in
Figure S4. (n = 4 mice per group.) *p < 0.05; **p < 0.01; ***p < 0.001.
(C and D) HSL and ATGL mRNAs were measured by RT-qPCR in ep-
ididymal WAT from PPARa/ mice infected with either control (Con)
or FGF21-expressing (FGF) adenovirus for 5 days (C) and WT mice ad-
ministered vehicle (Veh) or the PPARa agonist Wy14,643 (Wy; 0.1% in
chow) for 5 days (D). (n = 4 mice per group.) *p < 0.05; **p < 0.01.
(E) Serum free fatty acid concentrations were measured in fed WT and
Tg mice (left panel) or WT mice injected with FGF21 (FGF; 0.75 mg/kg/
day, subcutaneous) or vehicle alone (Veh) for 3 days (right panel). (n = 4
mice per group.) *p < 0.05; **p < 0.01.
(F) Glycerol release was measured from 3T3-L1 adipocytes treated
with vehicle alone (,), 0.5 nM FGF21 (-), or 5 nM isoproterenol (B)
for the indicated times. Assays were performed in triplicate.ell Metabolism 5, 415–425, June 2007 ª2007 Elsevier Inc. 419
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Core body temperature was measured by te-
lemetry in wild-type (WT) mice (open symbols)
and FGF21 transgenic (Tg) mice (closed sym-
bols) fasted for 24 hr ([A], top panel), WT mice
infected with a control adenovirus (open
symbols) or an FGF21-expressing adenovirus
(closed symbols) for 5 days (B), and WT mice
treated with vehicle (open symbols) or
Wy14,643 (0.1% in chow; closed symbols) for
5 days prior to initiating a 24 hr fast (C). In the
bottom panel of (A), locomotor activity was
measured during the 24 hr fast. (n = 4 mice
per group.) For each experiment, the area un-
der the curve (AUC) for body temperature or
locomotor activity during the entire 24 hr period
was calculated using GraphPad Prism soft-
ware. *p < 0.05; **p < 0.01; ***p < 0.001.of torpor (Zhang et al., 2006). Since FGF21 also induces
these lipases, we examined whether it affects torpor by
implanting body temperature telemeters in wild-type and
FGF21 transgenic mice. The basal core body temperature
of FGF21 transgenic mice was consistently 1C–2C lower
than that of wild-type mice (Figure 6A, top panel). More-
over, during a 24 hr fast, FGF21 transgenic mice entered
torpor, whereas wild-type mice did not (Figure 6A, top
panel). A similar induction of torpor was observed in
wild-type mice infected with an FGF21-expressing adeno-
virus compared to a control adenovirus (Figure 6B). To ex-
amine whether core body temperature is also affected un-
der conditions in which endogenous FGF21 is increased,
telemetry experiments were performed in wild-type mice
treated with either the PPARa agonist Wy14,643 or vehicle
alone. Administration of Wy14,643 resulted in reductions
in both basal and fasting-induced body temperature (Fig-
ure 6C). However, as noted above, mice fed chow con-
taining Wy14,643 were hypophagic and weighed less at
the end of the study than mice fed the control diet, com-
plicating interpretation of these results. Taken together,
the telemetry data demonstrate that FGF21 stimulates
fasting-induced torpor.420 Cell Metabolism 5, 415–425, June 2007 ª2007 Elsevier InTo examine whether the FGF21-induced changes in
body temperature are associated with decreased physical
movement, locomotor activity was measured in wild-type
and FGF21 transgenic mice during a 24 hr fast. Interest-
ingly, locomotor activity was dramatically reduced in
FGF21 transgenic mice (Figure 6A, bottom panel). These
data reveal that FGF21 alters behavior to conserve energy
and suggest that it reduces body temperature in part by
decreasing physical activity.
DISCUSSION
It is well established that PPARa plays a central role in the
starvation response by directly stimulating the transcrip-
tion of genes involved in fatty acid oxidation and ketone-
body production (Kersten et al., 2000; Lefebvre et al.,
2006). In this report, evidence is presented that PPARa
plays an even broader role during starvation by inducing
the hormone FGF21 in liver. Gain-of-function experiments
reveal that FGF21 regulates diverse processes associated
with fasting and energy conservation including lipolysis,
ketogenesis, physical activity, and torpor. In the accom-
panying paper by Badman et al. (2007) in this issue ofc.
Cell Metabolism
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ments demonstrate that FGF21 is required for maximal
hepatic lipid oxidation and ketogenesis induced by a keto-
genic diet. These two alternative approaches show that
the PPARa-FGF21 signaling cascade regulates ketogene-
sis caused by either fasting or dietary manipulation and
further suggest that this pathway is an important com-
ponent of the adaptive response to long-term nutrient
deprivation.
FGF21 and Ketogenesis
While ketone bodies are a crucial energy source during
fasting and starvation, their overproduction causes ketoa-
cidosis, which can lead to coma and death. Thus, keto-
genesis must be tightly coupled to energy demands. Much
of the regulation of ketogenesis during starvation is medi-
ated directly by PPARa, which induces HMGCS2, CPT1a,
and numerous other genes required for fatty acid oxida-
tion and metabolism by binding directly to DNA response
elements in their promoters (Erol et al., 2004; Hashimoto
et al., 2000; Hsu et al., 2001; Kersten et al., 1999; Leone
et al., 1999; Rodriguez et al., 1994). We now present evi-
dence that PPARa also promotes ketone-body produc-
tion by inducing FGF21. Unlike PPARa, FGF21 did not
stimulate ketogenesis by increasing mRNAs encoding
CPT1a, HMGCS2, or other proteins involved in fatty acid
oxidation. Thus, FGF21 induces ketone-body production
through a mechanism distinct from that previously de-
scribed for PPARa. Notably, protein levels of HMGCS2
and CPT1a were significantly increased in livers of FGF21
transgenic mice, suggesting a molecular basis for at least
part of the effect of FGF21 on ketone-body production.
Previous studies showed that infusion of exogenous
fatty acids or induction of lipolysis without changing the
activity of the ketogenic enzymes is sufficient to induce
ketogenesis (Avogaro et al., 1992; Bates et al., 1976;
Beylot et al., 1987). Several lines of evidence indicate that
FGF21 also induces ketogenesis by stimulating lipolysis,
thereby increasing the supply of free fatty acids to the
liver. First, FGF21 transgenic mice have markedly smaller
white adipocytes than their wild-type counterparts, sug-
gesting that the adipocytes are depleted of lipid (Kharito-
nenkov et al., 2005). Second, both FGF21 transgenic mice
and wild-type mice administered recombinant FGF21 had
significant increases in serum free fatty acid concentra-
tions, indicative of increased lipolysis. Third, FGF21 en-
hanced lipolysis in 3T3-L1 adipocytes, suggesting that
FGF21 acts directly on WAT to stimulate lipolysis.
FGF21 was previously shown to stimulate glucose up-
take in 3T3-L1 adipocytes (Kharitonenkov et al., 2005).
The finding that FGF21 stimulates both glucose uptake
and lipolysis in adipocytes—and causes corresponding
increases in insulin sensitivity and circulating free fatty
acid levels in vivo—is surprising since these processes
are regulated in opposite directions by both insulin and
catecholamines. FGF21 was shown previously to increase
glucose transporter 1 expression in adipocytes, which
may account for its effects on glucose uptake (Kharitonen-
kov et al., 2005). However, the mechanisms underlying itsClipolytic actions remain unclear. Adrenaline and noradren-
aline concentrations were reduced in urine of FGF21
transgenic mice, indicating that FGF21 does not cause
systemic increases in catecholamines. While mRNA and
protein levels of HSL and ATGL were increased in WAT
of FGF21 transgenic mice, they were not induced by
FGF21 in 3T3-L1 adipocytes in short-term experiments
in which lipolysis was increased. Additional studies will
be required to determine how FGF21 stimulates lipolysis
and the relationship between its effects on glucose and
fatty acid metabolism.
A role for FGF21 in increasing hepatic concentrations
of free fatty acids is also supported by its effects in
liver. FGF21 caused striking increases in hepatic levels
of mRNAs encoding the pancreatic lipases PNLIP,
PNLIPRP2, and CEL. During fasting, a substantial fraction
of free fatty acids taken up by the liver are re-esterified to
triglyceride (Baar et al., 2005). Thus, induction of lipases
by FGF21 may provide a mechanism for the efficient hy-
drolysis of hepatic triglyceride stores, especially during
long-term nutritional deficiency (see below). Consistent
with this hypothesis, FGF21 administration caused a sig-
nificant reduction in the hepatic hypertriglyceridemia that
occurs in fasted PPARa/ mice.
Based on all of the data, we propose the following
model for how PPARa induces ketogenesis during fasting
(see Figure 7). In liver, PPARa directly stimulates the tran-
scription of CPT1a,HMGCS2, and other genes involved in
the uptake and catabolism of fatty acids by binding to
DNA response elements in their promoters. PPARa also
induces hepatic expression of FGF21, which acts in an
autocrine/paracrine fashion to increase CPT1a, HMGCS2,
and pancreatic lipase levels in liver and in an endocrine
manner to stimulate lipolysis in WAT. The net result of this
bipartite mechanism is the stimulation of ketogenesis by
increasing both the supply of free fatty acids to the liver
and the concentrations of proteins required for ketone-
body production.
Figure 7. Model for the Coordinate Actions of PPARa and
FGF21 during Fasting
In liver, PPARa directly induces transcription of enzymes and trans-
porters required for fatty acid (FA) oxidation and ketogenesis. PPARa
also induces FGF21, which through endocrine and autocrine/paracrine
mechanisms promotes lipolysis in white adipose tissue and liver,
stimulates ketogenesis in liver, and enhances torpor.ell Metabolism 5, 415–425, June 2007 ª2007 Elsevier Inc. 421
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Our finding that FGF21 induces pancreatic lipases in liver
was interesting in light of a recent report that PNLIPRP2
and CLPS are also induced in mouse liver during torpor,
the murine equivalent of hibernation (Zhang et al., 2006).
These data, together with the finding that PNLIP is in-
duced in extrapancreatic tissues by hibernation in ground
squirrels (Andrews et al., 1998; Bauer et al., 2001), sug-
gested that FGF21 might regulate torpor. Indeed, FGF21
transgenic mice entered torpor during fasting, whereas
wild-type mice did not. Infection of mice with an FGF21-
expressing adenovirus also stimulated torpor. Notably,
ketone-body concentrations are markedly elevated during
torpor and hibernation (Krilowicz, 1985; Rauch and
Behrisch, 1981). Thus, FGF21 regulates key aspects of the
global torpor response including lipase expression, keto-
genesis, and body temperature.
Why are pancreatic lipases induced in other tissues
during torpor and hibernation? One possible reason is
the unique biochemical properties of these lipases, which
evolved to function in the harsh conditions encountered in
the gut. For example, PNLIP is 10-fold more efficient than
HSL at hydrolyzing triglycerides and retains full activity
at temperatures as low as 0C (Andrews et al., 1998; Fre-
drikson et al., 1981). Moreover, the activities of PNLIP and
other pancreatic lipases are unaffected by catechol-
amines, which are ineffective at stimulating lipolysis at
low temperatures (Dark et al., 2003; Moreau-Hamsany
et al., 1988). Thus, the extrapancreatic induction of pan-
creatic lipases by FGF21 may ensure the continuous
delivery of free fatty acids to tissues even under adverse
environmental conditions in which the conventional
catecholamine-regulated lipase pathways are compro-
mised.
Broader Implications of the PPARa-FGF21 Pathway
The studies presented in this paper focus on the roles
of the PPARa-FGF21 pathway in regulating fatty acid me-
tabolism, ketogenesis, and torpor. The similar effects of
PPARa agonists and FGF21 on these parameters, to-
gether with the finding that FGF21 partially reverses the
hypoketonemia and hypertriglyceridemia in PPARa/
mice, suggest that FGF21 contributes to the pleiotropic
actions of PPARa. Additional similarities in the pharmaco-
logical profiles of PPARa agonists and FGF21 further sug-
gest that the implications of this signaling cascade are
likely to be broader. For example, both fibrates and
FGF21 lower LDL cholesterol, raise HDL cholesterol, and
improve insulin sensitivity in dyslipidemic rhesus monkeys
(Kharitonenkov et al., 2007; Winegar et al., 2001). Further-
more, both PPARa agonists and FGF21 prevent diet-
induced obesity and enhance insulin sensitivity in rodents
(Chou et al., 2002; Guerre-Millo et al., 2000; Kharitonen-
kov et al., 2005; Tsuchida et al., 2005). This striking over-
lap in activities suggests that FGF21 contributes to many
of the actions of PPARa agonists. The finding that FGF21
is induced by PPARa in human hepatocytes raises the
intriguing possibility that FGF21 also contributes to the
therapeutic actions of the fibrate drugs.422 Cell Metabolism 5, 415–425, June 2007 ª2007 Elsevier IncIn closing, the identification of the PPARa-FGF21 sig-
naling cascade reveals an unexpected endocrine pathway
originating in the liver that regulates diverse components
of the adaptive starvation response, including ketogenesis
and torpor. Moreover, this finding extends the relationship
between nuclear receptors and the FGF15/21/23 subfam-
ily of endocrine hormones. It was previously shown that
the bile acid receptor FXR induces FGF15 to regulate bile
acid homeostasis (Inagaki et al., 2005; Li et al., 2005) and
that the vitamin D receptor induces FGF23 to regulate
phosphate and vitamin D homeostasis (Kolek et al.,
2005). The finding that FGF21 is regulated by PPARa dem-
onstrates that each member of this unusual FGF subfamily
is regulated by a corresponding nuclear receptor. The in-
duction of endocrine FGFs provides a mechanism for nu-
clear receptors to extend their biological actions to tissues




All experiments were performed with male mice. PPARa/ mice on
a pure 129S4/Sv background were purchased from The Jackson Lab-
oratory. Mice were fed standard chow containing 4% fat ad libitum. All
animal experiments were approved by the Institutional Animal Care
and Research Advisory Committee of the University of Texas South-
western Medical Center.
For the fasting and refeeding experiment presented in Figure 1C,
mice were divided into three groups: nonfasted, fasted, and refed.
The nonfasted group was fed ad libitum, the fasted group was fasted
for 12 hr, and the refed group was fasted for 12 hr and then refed regular
chow diet for 12 hr. The starting times for the feeding regimens were
staggered so that all mice were killed at the same time at the end of the
dark cycle. Liver mRNA prepared from the 12 hr fed and fasted groups
was also used for the RT-qPCR experiments shown in Figure 4D. For all
other fasting experiments, mice were fasted for 24 hr and killed at the
end of dark cycle. For experiments with Wy14,643 (Chemsyn Science
Laboratories), mice were fed chow with 0.1% Wy14,643 admixed.
For core body temperature and locomotor activity measurements,
TAF2 telemetric temperature transmitters (Data Sciences International)
were implanted in the peritoneal cavity under general anesthesia. Mice
were allowed to recover for >7 days. Data from mice individually
housed at 22C were collected and analyzed using ART2.1 software
(Data Sciences International).
To generate the FGF21 transgenic mice, a cDNA containing the
mouse FGF21 coding region was inserted into the MluI and XhoI sites
of pLiv7 (Miyake et al., 2001; Simonet et al., 1993). The 6.7 kb SalI-SpeI
fragment of pLiv7-FGF21 was injected into fertilized eggs as previously
described (Shimano et al., 1996). Transgenic mice were generated and
maintained on a C57BL/6J background. Two independent FGF21
transgenic mouse lines were established that had hepatic FGF21
mRNA concentrations 50-fold (line 1) and 150-fold higher (line 2)
than those in fasted wild-type mice. The two lines had virtually identical
changes in fasting serum b-hydroxybutyrate, triglyceride, total choles-
terol, glucose, and insulin concentrations (data not shown). All addi-
tional experiments were performed with line 1.
Recombinant FGF21
Recombinant mouse FGF21 (residues 33–209) was expressed in
E. coli, refolded in vitro, and purified to homogeneity by sequential
affinity, ion exchange, and size exclusion chromatography as previ-
ously described (Plotnikov et al., 2000)..
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The FGF21 coding region was cloned into the pACCMVpLpA()loxP
vector at unique BamHI and HindIII sites. Virus was propagated and
purified as described (Aoki et al., 1999; Gerard and Meidell, 1995).
Mice were infected with adenovirus by jugular vein injection using
a 3/10 cc syringe (Becton, Dickinson and Company). Each mouse re-
ceived 7.53 109 particles/g body weight in 0.1 ml of saline. Four days
after injection, mice were kept under fed or fasted conditions for 24 hr.
Metabolite Measurements
Total lipids were extracted from 50 mg of liver as previously de-
scribed (Folch et al., 1957). Triglyceride content of liver and plasma tri-
glyceride concentrations were measured using an L-type TG H triglyc-
eride kit (Wako Chemicals Inc.). Plasma free fatty acids were measured
using a NEFA C kit (Wako Chemicals Inc.). Plasma b-hydroxybutyrate
concentrations were measured using a D-3-hydroxybutyric acid kit
(R-Biopharm AG).
Perfused Liver Experiments
Livers from fed FGF21 transgenic mice or wild-type littermates were
isolated and perfused for 60 min in a nonrecirculating fashion at
8 ml/min with a Krebs-Henseleit-based perfusion medium containing
1.5 mM lactate, 0.15 mM pyruvate, 0.25 mM glycerol, and 0.4 mM
free fatty acid (algal mix bound to 3% albumin) as described (Burgess
et al., 2004). Ketone production was determined by standard biochem-
ical assays of the effluent perfusate.
Human Hepatocytes
Human primary hepatocytes were obtained from the Liver Tissue Pro-
curement and Distribution System as attached cells in six-well plates in
human hepatocyte maintenance medium (Cambrex Bio Science Wal-
kersville Inc.) supplemented with 100 nM dexamethasone, 100 nM in-
sulin, 100 U/ml penicillin G, and 100 mg/ml streptomycin. Twelve hours
after changing the culture medium to serum-free Williams’ E medium,
cells were treated with 1 mM GW7647 or vehicle (0.1% DMSO).
Plasmids and Transient Transfection Assays
The FGF21 promoter constructs 1497/+5, 977/+5, and 98/+5
were generated by PCR using 129Sv mouse genomic DNA and the fol-
lowing oligonucleotides: 1497 forward, 50-GACGGCAAGCTTGGCC
TGAAGCCTCACCTTGAC-30; 977 forward, 50-CCCAAGCTTCCAAA
GCACCTTGTAGCTTAA-30; 98 forward, 50-GACGGCAAGCTTGGTT
CCTGCCAAGTGTGTC-30; +5 reverse, 50-GACGGCCTCGAGTGTCTG
GTGAACGCAGAAATACCC-30. The PCR-amplified fragments were
cloned into a luciferase reporter construct using HindIII and XhoI sites.
To generate the 66/+5 fragment, the following oligonucleotides were




CCACTCCTGA-30. The annealed oligonucleotides were cloned into a
luciferase reporter using HindIII and XhoI sites. All constructs were ver-
ified by DNA sequencing.
For transient transfection assays, CV-1 cells were maintained in
DMEM containing 10% fetal bovine serum supplemented with L-gluta-
mine and antibiotics. Cells were plated in 96-well plates at a density of
10,000 cells per well. After 24 hr, cells were transfected using Lipofect-
amine 2000 (Invitrogen). Each well was transfected with 20 ng ofFGF21
reporter gene, 5 ng of CMX or CMX-mouse PPARa, and 20 ng of CMV-
b-galactosidase. pGEM was added to bring the total DNA to 110 ng/
well. After overnight transfection, cells were treated with GW7647 or
vehicle alone (0.1% DMSO) in delipidated medium for 24 hr before per-
forming luciferase and b-galactosidase assays. Luciferase activity was
normalized to b-galactosidase activity.
Chromatin Immunoprecipitation
Frozen adult mouse liver was crushed into powder. DNA-protein
crosslinking was performed by incubating powdered liver tissueC(50 mg) with 1% formaldehyde in PBS containing 1 mM DTT and 1 mM
PMSF for 10–15 min at room temperature with gentle shaking. Cross-
linking reactions were stopped by adding glycine to 0.125 M. Liver nu-
clei were isolated with a Dounce homogenizer in hypotonic solution
followed by centrifugation at 4000 3 g for 1 min. Chromatin immuno-
precipitation assays were performed with liver nuclei using a ChIP as-
say kit (Upstate Biotechnology) and anti-PPARa antibody (5 mg, Affinity
BioReagents) or control rabbit IgG (Santa Cruz Biotechnology). Precip-
itated DNA was purified using a spin column (QIAGEN) and eluted
in 100 ml water. DNA (1.25 ml) was subjected to RT-qPCR analysis as
described (Bookout and Mangelsdorf, 2003) using the following oligo-
nucleotides: FGF21 6533/6470 forward, 50-TCAGCATGCCTCC
AAAGC-30, reverse, 50-TCAGCCTTGAGGAAGAGTAGACA-30; FGF21
1119/1044 forward, 50-AGGGCCCGAATGCTAAGC-30; reverse,
50-AGCCAAGCAGGTGGAAGTCT-30.
In Vitro Lipolysis Assay
3T3-L1 mouse fibroblasts were differentiated into adipocytes using
a standard differentiation protocol (Student et al., 1980). Briefly, cells
were grown to confluency and incubated for 2 days in an induction
cocktail consisting of DMEM with 10% FBS, 10 mg/ml insulin,
0.5 mM IBMX, and 0.25 mM dexamethasone. Cells were maintained
in differentiation media consisting of DMEM with 10% FBS and
10 mg/ml insulin for 4 days, followed by a 2 day incubation in DMEM
with 10% FBS alone. Glycerol release was measured using an adipoly-
sis assay kit (Chemicon).
RT-qPCR Analysis
Primers were designed using Primer Express software (Applied Bio-
systems) based on GenBank sequence data. All primer sequences
were BLASTed against the NCBI mouse genomic sequence database
to ensure unique specificity. Primer sequences are listed in Table S2.
RT-qPCR reactions (10 ml) contained 25 ng of cDNA, 150 nM of each
primer, and 5 ml of SYBR Green PCR Master Mix (Applied Biosystems).
All reactions were performed in triplicate on an Applied Biosystems
Prism 7700HT sequence detection system, and relative mRNA levels
were calculated by the comparative threshold cycle method by using
cyclophilin or apolipoprotein B as the internal control (Bookout and
Mangelsdorf, 2003).
Immunoblot Analysis
For CPT1a and HMGCS2 immunoblotting, 100 mg of liver was homog-
enized in 1 ml buffer A (10 mM Tris-HCl [pH 7.4], 5 mM EDTA, 150 mM
NaCl, 30 mM sodium phosphate, 10% glycerol, 0.5% NP40 containing
Complete protease inhibitor cocktail [Roche Diagnostics]) using a Poly-
tron homogenizer. After centrifugation at 16,000 3 g for 5 min at 4C,
the supernatant was collected. Immunoblotting was performed using
antibodies against CPT1a (Esser et al., 1993), HMGCS2 (Santa Cruz
Biotechnology), and b-actin (Sigma-Aldrich). For HSL and ATGL immu-
noblotting, epididymal WAT was homogenized in buffer A. Samples
were centrifuged at 16,0003 g for 25 min at 4C, and the supernatant
was collected. Immunoblotting was performed using antibodies
against HSL (Santa Cruz Biotechnology), ATGL (Cell Signaling Tech-
nology), and b-actin (Sigma-Aldrich).
Statistical Analyses
Statistical analyses were performed using Minitab Release 14 software
(Minitab Inc.). Comparisons of two groups were performed using
Student’s t test. p < 0.05 was considered significant.
Supplemental Data
Supplemental Data include two tables and six figures and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/
full/5/6/415/DC1/.ell Metabolism 5, 415–425, June 2007 ª2007 Elsevier Inc. 423
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